Sign In
Search Icon
Menu Icon

COVID-19 Therapeutics Thresholds, Orders, and Replenishment

Providers have the ability to order COVID-19 therapeutic products seven days a week through the Health Partner Ordering Portal (HPOP) in a process known as “threshold and replenishment.” In this process, the federal government replenishes the available supply, replacing products ordered by sites in the jurisdiction on a regular cadence (currently on a monthly basis). This ensures that the total amount of product available to jurisdictions is consistent, and this amount is known as a "threshold quantity."

Paxlovid (nirmatrelvir co-packaged with ritonavir) and Lagevrio (molnupiravir) threshold amounts are determined on a pro rata population basis and replenishment occurs monthly.

Requests for additional products can be made by central partners, including state and territorial health department officials, at any time if the current supply is not sufficient to meet demand. The federal government tracks the amount of COVID-19 therapeutic products ordered through the HPOP portal each week, monitoring product availability for each state or territory.

COVID-19 Therapeutics Summary: For All Open Distribution Channels1

December 17, 2021 –August 28, 2023

Therapeutic Courses Delivered Courses Administered2
Paxlovid3 15,440,583
9,918,591
Lagevrio
3,258,701
1,444,689
Total:
View Data by Jurisdiction
18,699,284 11,363,280

States, territories, and federal entities, including HRSA
Based on 91​% of sites reporting this week
Includes Paxlovid and Renal Paxlovid

  • Data Source: Tiberius, Updated 08/28/2023 as of 1:00p EDT
  • Data through Sunday, 08/27/2023

COVID-19 Therapeutics Summary: Previously Distributed Products

2020 – 2023

Therapeutics
(currently not in use*)
Date of
First Issue
Date of
Last Distribution
Courses
Delivered
Courses
Administered
Evusheld (300mg doses) December 8, 2021 January 26, 2023 1,032,156 738,936
Bebtelovimab February 11, 2022 November 30, 2022 739,889 624,633
Sotrovimab May 26, 2021 April 5, 2022 706,692 302,209
Bamlanivimab/Etesevimab February 9, 2021 January 24, 2022 642,125 610,753
REGEN-COV November 21, 2020 January 24, 2022 2,878,138 2,078,587
Bamlanivimab** November 9, 2020 March 2, 2021 664,691 N.A.

*Products are not currently authorized for use in any U.S region due to high frequency of SARS-CoV-2 subvariants to which these therapeutics are unlikely to be effective.

**EUA was revoked for bamlanivimab when administered alone; courses administered data are not available at this time.

COVID-19 Therapeutics Threshold Determinations

May 1, 2023 - October 1, 2023

Monthly Threshold Determinations* Paxlovid
(nirmatrelvir co-packaged with ritonavir;
standard and reduced dose)
Lagevrio
(molnupiravir)
Total
August 28 - October 1, 2023 2,452,230 195,299 2,647,529
July 31 - August 27, 2023 2,452,230 195,299 2,647,529
July 1 - July 30, 2023 2,452,230 195,299 2,647,529
June 1 - June 30, 2023 2,450,200 194,911 2,645,111
May 1 - May 31, 2023 2,450,200 194,911 2,645,111

*Starting May 2023, COVID-19 therapeutic threshold determinations are made on a monthly cadence.

Prior COVID-19 Therapeutic Product Efforts

Date Range Threshold/Distribution/Allocation by Jurisdiction
April 25, 2022 - April 30, 2023
COVID-19 Therapeutics Threshold Determinations
September 13, 2021 - April 24, 2022 COVID-19 Therapeutics Distribution
November 9, 2020 - March 2, 2021 Bamlanivimab Distribution
November 24, 2020 - February 2, 2021 REGEN-COV Distribution
July 6, 2020 - October 4, 2020 Allocation of Commercial Veklury (Remdesivir) (PDF)
May 4, 2020 - June 29, 2020
Allocation of Donated Veklury (Remdesivir)